Back

State of the Art - Novel targets in anti thrombotic drug development

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: New developments in anti thrombotic drug therapy Risk Factors and Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Bianca Rocca

LUM University, Casamassima (Italy)

3 More presentations in this session

Presentation thumbnail
Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin
Assistant Professor C. Koh (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients
Professor R. Storey (Sheffield, GB)
Abstract Slides Video
Presentation thumbnail
Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452
Professor L. Jennings (Memphis, US)
Abstract Slides Video

Access the full session

Session thumbnail
New developments in anti thrombotic drug therapy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Making personalised prevention everyone's business
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
thumbnail
Webinar
Risk assessment and lipid management in primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources